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Summary
Malignant pleural effusion (MPE) is a poor prognostic sign for cancer
patients, whereas the functional condition of MPE CD81 T cells is
unknown. Intracavitary immunotherapy with interleukin (IL)-2 has been
proven effective in controlling MPE. To elucidate the underlying
mechanism, 35 lung cancer (LC) patients with MPE and 12 healthy donors
were included in this study. For the IL-2 therapy experiments, after draining
partial MPE, we treated 14 patients by administrating IL-2 (3 or 5 3 106 U
in 50 ml saline) into the thoracic cavity. Before and after IL-2 treatment (40-
48 h), the MPE and peripheral blood (PB) were obtained from the subjects.
PB from healthy volunteers was collected as control. The expression of
programmed cell death 1 (PD-1), granzyme B (GzmB), interferon (IFN)-g
and the proliferation were analysed in CD81 T cells from MPE and PB. The
CD81 T cells in the MPE of LC patients showed lowest GzmB, IFN-g and
proliferation but highest PD-1 expression, compared with that in PB of LC
patients and healthy donors. IL-2 treatment reduced the expression of PD-1,
increased the expression of GzmB and IFN-g and enhanced the
proliferation of CD81 T cells in MPE. In addition, IL-2 treatment reduced
carcino-embryonic antigen (CEA) level in MPE. These results indicate that
MPE CD81 T cells exhibit exhaustion phenotype which can be reversed by
IL-2 therapy.
Keywords: Granzyme B, interferon-g, IL-2, malignant pleural effusion,
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Introduction
As one of the most malignant tumours with the fastest-
growing mortality, the incidence and fatality rates of lung
carcinoma have increased in the past decades [1]. One of
the complications that occur as a result of advanced lung
cancer (LC) is malignant pleural effusion (MPE). As well as
causing shortness of breath or chest discomfort, MPE is
also correlated with worse outcomes and a poor prognosis.
The average life expectancy of MPE is as few as 6 months
[2]. Thus, controlling the development of MPE is essential
for improving the prognosis of LC patients.
Recent studies have identified that cancer-specific T cells
are largely dysfunctional, exhibiting exhaustion phenotype,
which contributes to tumour immune escape and metastasis
[3–5]. These exhausted CD81 T cells manifest as a reduced
secretion of cytokines, including interleukin (IL)-2, gran-
zyme B (GzmB) and interferon (IFN)-g, decreased cell via-
bility and proliferation, as well as enhanced apoptosis [6,7].
In addition, elevated expression of programmed cell death 1
(PD-1), an immune inhibitory receptor, is a signature for T
cell exhaustion [8,9]. The activation of PD-1 inhibits T lym-
phocyte activation and expansion and cytokine production
[10–13], while blocking PD-1 breaks T cell immune toler-
ance to tumour cells and enhances anti-tumour immunity
[14–18]. Akin to the tumour microenvironment, abundant
immune cells, including CD81 T cells, accumulate in the
MPE [19]. The exhausted phenotype of CD81 T cells in the
tumour microenvironment suggests the possibility that
MPE CD81 T cells might also be dysfunctional.
Traditional ways for controlling MPE include thoracent-
esis, intrapleural chemical, talc pleurodesis and indwelling
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pleural catheter [20–23]. Apart from these methods,
immunotherapy has been broadly used to treat cancer by
provoking the immune system [24], among which IL-2
intrapleural administration in MPE is a representative
method [25]. IL-2 therapy prolongs patients’ survival [26],
increases the numbers of CD31 T cells and natural killer
(NK) cells, enhances the immune response and reduces the
incidence of MPE [27,28], and the efficacy rate of control-
ling MPE was 59% with no significant side effects
[29–33]. In addition, a recent study suggested that
IL-2 administration enhanced CD81 T cell responses and
decreased inhibitory receptor levels, including PD-1,
on virus-specific CD81 T cells in chronic lymphocytic cho-
riomeningitis virus (LCMV)-infected mice [34]. These
findings suggest that intrapleural IL-2 therapy may affect
the functions of CD81 T cells in MPE.
In this study, we obtained MPE and peripheral blood
(PB) samples from LC patients and attempted to assess
the CD81 T cell phenotype in MPE prior to and after the
well-established IL-2 intrapleural therapy compared with
CD81 T cells in PB of healthy controls. Our results indi-
cate a novel notion that intrapleural IL-2 therapy
improves MPE by reversing CD81 T cell exhaustion in
MPE.
Fig. 1. Immune function of CD81 T cells in the MPE of LC is immunosuppressed. (a,b) Cytokine expression in CD31CD81 T cells in PB and
MPE: GzmB (a) and IFN-g (b). Representative dot-plots were gated on CD31CD81 T cells in flow cytometry analysis. *P< 005; **P< 001;
***P< 0001.
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Materials and methods
Patients
We examined 35 patients with histologically diagnosed LC
with MPE at the Xinqiao Hospital, the Third Military Med-
ical University (Chongqing, China), between September
2013 and July 2016, and 12 healthy volunteers, as listed in
the Supporting information, Tables S1 and S2. Patients
who were confirmed with metastatic non-small cell lung
cancer (NSCLC) or small cell lung cancer (SCLC) with
MPE and did not require recombinant human (rh)IL-2
chemotherapy were included. The Eastern Cooperative
Oncology Group Performance Status Scale (ECOG PS) was
0–2. The main exclusion criterion was the requirement for
a high dose of immunosuppressive treatment (prednisone
equivalent dose> 10 mg/day). Moreover, patients with
fever showing evidence of ischaemic heart disease and sig-
nificant arrhythmias were excluded. In the experiments
examining PD-1, GzmB and IFN-g in blood and MPE,
patient characteristics are shown in the Supporting infor-
mation, Table S1. This study meets the ethical principles
and requirements of our committee (Ethics Committee,
Xinqiao Hospital, Third Military Medical University) and
complies with the Declaration of Helsinski. All participants
in this study provided written informed consent.
Recombinant human (rh)IL-2 treatment in the MPE
of LC
The rhIL-2 was dissolved in 50 ml saline solution and
infused continuously into the pleural cavity after the MPE
were drained. The rhIL-2 dose depended upon patient sta-
tus: if patients were in a poor state (poor vital signs or
cachexia), 3 3 106 U were used, otherwise 5 3 106 U were
used. The details are described in the Supporting informa-
tion, Table S2. Before and after IL-2 treatment (40–48 h),
MPE and PB were obtained from the patients.
Flow cytometric analysis of PD-1, GzmB and IFN-g on
CD81 T cell in the blood and MPE
Peripheral blood mononuclear cells (PBMC) from
healthy volunteers and LC patients with MPE and mono-
nuclear cells (MC) from MPE of LC patients were isolated
by density gradient centrifugation using human PB
Fig. 2. CD81 T cells in the MPE of LC show the
lowest proliferation capacity. (a) Proliferation of
CD31CD81 T cells [stained with carboxy
fluorescein succinimidyl ester (CFSE)] in PB of
healthy control and LC patients, as well as in the
MPE of LC patients. (b) The percentage in each
generation with CFSE dilution. DT 5 division
time; MFI 5 mean fluorescent intensity;
DI% 5 division percentage; PI 5 proliferation
index; DI 5 division index. The non-paired t-
test, *P< 005, PB versus MPE.
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lymphocyte separation medium (Ficoll; TBD, Tianjin,
China). 1 3 106 cells were stained with antibodies
including CD3-fluorescein isothiocyanate (FITC), CD8-
allophycocyanin (APC), CD279-phycoerythrin (PE) (PD-
1-PE; BD Biosciences, San Jose, CA, USA) and analysis
using the fluorescence activated cell sorter (FACS)Calibur
(BD Biosciences).
For GzmB and IFN-g staining, cells (1 3 106) were acti-
vated with anti-CD3 antibody (T&L Biotechnology, Bei-
jing, China) and rhIL-2 (Shuanglu Pharm, Beijing, China),
treated with phorbol 12-myristate 13-acetate (PMA, 50 ng/
ml; Sigma, St Louis, MO, USA), ionomycin (Ion, 1 lg/ml;
Sigma) and GolgiPlug protein transport inhibitor (1 ll/ml;
BD Biosciences) and were cultured subsequently for 4 h
(378C; 5% CO2). The cells were harvested and stained with
CD3-FITC and CD8-peridinin chlorophyll (PerCP). After
fixation and permeabilization using the Cytofix/Cytoperm-
Plus Fixation/Permeabilization Kit (BD Biosciences), intra-
cellular staining was conducted using Alexa Fluor 647
mouse immunoglobulin (Ig)G1j isotype control, Alexa
Fluor 647 mouse anti-human GzmB or IFN-g-APC
(human; BD Biosciences). GzmB and IFN-g expression
was analysed with flow cytometry.
CD81 T cell proliferation assay
The MC in the MPE and PBMC were stained with carboxy
fluorescein succinimidyl ester (CFSE; Dojindo Laboratories,
Shanghai, China); 1 3 107 PBMC/MC were incubated in
phosphate-buffered saline (PBS) with a final concentration
of CFSE (2 lM) for 20 min at 378C. After washing, the
labelled cells (1 3 106 cells/well) were incubated in the pres-
ence of anti-CD3 antibody and rhIL-2 for 5 days. The cells
were harvested and stained with CD3-PE and CD8-APC
(BD Biosciences) and analysed by flow cytometry. The divi-
sion percentage (D%), proliferation index (PI) and division
index (DI) were used to quantify T cell division. D% 5 (the
number of cell divisions)/(total cell numbers) 3 100%.
DI 5 the average number of divisions that a cell (present in
the starting population) has undergone; PI 5 (sum of the
cells in all generations)/(computed number of original par-
ent cells theoretically present at the start of the experiment.
PI is the proportional to the percentage of cells that have
proliferated in culture. These indexes were calculated using
FlowJo software (Tree Star, Ashland, OR, USA).
PBMC stimulation with rh-IL-2 in vitro
PBMC (3 3 106 cells/well) from LC patients were seeded in
six-well plates with or without 2000 U/ml of IL-2 treatment
for 48 h. The cells were then harvested for PD-1, GzmB and
IFN-g staining. For the groups staining with CFSE, the cells
were cultured with anti-CD3 antibody and rhIL-2 for 72 h.
Measurement of carcinoembryonic antigen (CEA) in
MPE of LC
The MPE supernatant of LC patients was collected for CEA
examination by the Etiologies Department of Xiaoqiao
Hospital, Third Military Medical University (Chongqing,
China).
Statistical analysis
Reduction percentage of CEA and PD-1 was calculated
using the following equation: reduction (%) 5 100 3 (1–y/
x)%, where y and x represent the levels of CEA or PD-1 in
MPE after and before IL-2 treatment, respectively.
Fig. 3. High PD-1 expression of CD81 T cells in the MPE of LC
patients. (a) Frequencies of PD-1-expressing CD81 T cells in 13
blood samples from LC patients with MPE, 12 blood samples for
healthy controls and 13 MPE samples for LC, non-paired t-test.
(b) Representative dot-plots of PD-1 staining gated on CD31CD81
T cells. *P< 005; **P< 001; ***P< 0001.
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Statistical significance was calculated by paired and
unpaired t-tests, as indicated in the figure legends, with
P< 005 considered statistically significant.
Results
Immune dysfunction of CD81 T cells in MPE of LC
We first assessed the expression of GzmB, IFN-g and
the proliferation of CD81 T cells from three different
groups that comprised PB from healthy volunteers and LC
patients with MPE, as well as from MPE (Figs 1 and 2). In
accordance with our recent study [17], the percentage of
GzmB-expressing CD81 T cells in PB of LC patients was
significantly higher than that in MPE (P< 001). Of note,
the percentage of GzmB1CD81 T cells in PB of LC patients
was higher than that in PB of healthy controls, but there
were no significant differences in GzmB between PB from
LC patients and healthy controls (Fig. 1a). Consistently,
after stimulation with phorbol 12-myristate 13-acetate
(PMA) and ionomycin, MPE CD81 T cells produced less
IFN-g than PB CD81 T cells from either healthy controls
or LC patients (P< 005; Fig. 1b).
We then investigated the proliferation of CD81 T cells
from MPE and PB. We found that MPE CD81 T cells
showed the lowest proliferation capacity, while CD81 T
cell proliferation in the PB of LC patients and healthy con-
trols was significantly higher (Fig. 2a,b). These results illus-
trate that the function of CD81 T cells in MPE is impaired.
CD81 T cells express a high level of PD-1 in MPE of
LC
To validate further the functional condition of MPE CD81
T cells, we evaluated the percentage of PD-1-expressing
CD81 T cells in PB of healthy subjects and LC patients, as
Fig. 4. IL-2 regulates PD-1 expression and immune function in MPE and LC-PB CD81 T cells. (a) PD-1 expression on the CD81 T cell surface
in 14 MPE samples of LC patients by IL-2 treatment, and seven PB of LC patients in vitro. (b,c) The proportion of CD31CD81 T cells
producing GzmB and IFN-g. *P< 005; **P< 001; ***P< 0001.
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well as in MPE (Fig. 3a,b). The fraction of PD-1-expressing
CD81 T cells was highest in MPE (P< 001) and lowest in
PB of healthy donors (P< 005). PD-1-expressing CD81 T
cells in MPE were 158-fold greater than those in the PB of
patients (P< 001). The aforementioned results demon-
strate that CD81 T cells in the MPE of LC patients display
exhaustion phenotype.
IL-2 reversed the exhaustion phenotype of CD81 T
cells
Intrapleural administration of IL-2 was reported to be
effective in alleviating tumour-associated malignant
pleurisy [35]. We next wondered whether or not IL-2
played a role in regulating T cell function. We collected 14
specimens and perfused IL-2 into the thorax to treat the
MPE. We found that the fraction of PD-1-expressing
CD81 T cells was reduced significantly after IL-2 treatment
(Fig. 4a). In addition, the production of GzmB and IFN-g
by CD81 T cells was increased markedly in the MPE (Fig.
4b,c). Furthermore, IL-2 treatment enhanced the prolifera-
tion of MPE CD81 T cells, as the mean fluorescence inten-
sity (MFI) of CFSE was reduced significantly (Fig. 5a). To
investigate further whether the same phenomena also
occurred in LC-PB, the function and proliferation of CD81
T cells were determined after cells stimulated with or
Fig. 5. IL-2 restores MPE CD81 T cell proliferation. (a) CD81 T cells in the MPE were stained with CFSE and then incubated for 5 days (378C).
(b) Proliferation of CD31CD81 T cells (stained with CFSE) in PB of LC patients, with IL-2 treatment in vitro. The proliferation was examined
with flow cytometry.
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without rhIL-2 for 48 h in vitro. Compared with vehicle,
the percentage of PD-1-expressing in CD81 T cells and the
production of GzmB and IFN-g did not change signifi-
cantly after IL-2 treatment (Fig. 4). The IL-2 treatment also
enhanced the proliferation of LC-PB CD81 T cells (Fig.
5b). These results demonstrate that the magnitude change
of CD81 T cells in LC-PB CD81 T cells by IL-2 treatment
is not as significant as that in MPE.
IL-2 reduced CEA levels in MPE
To validate the correlation between IL-2 therapy and clini-
cal outcome we determined the CEA level, a key indicator
for tumour malignancy, in MPE. Consistent with the
results from PD-1 expression, IL-2 treatment reduced CEA
level in the supernatant of the MPE (P< 001; Fig. 6).
These results indicate that IL-2 treatment reverses signifi-
cantly the exhaustion of MPE CD81 T cells.
Discussion
The general approach for the palliative management of
symptomatic pleural effusions is chest tube drainage. Many
agents, including IL-2, have been administered into the
pleural space and have been shown to be effective in con-
trolling effusions [23]. However, the underlying mecha-
nism was unclear. In this study, we showed that the
function of MPE CD81 T cells was impaired with the
exhaustion phenotype, which was reversed by IL-2 treat-
ment. These findings suggest that MPE T cells are in an
exhausted condition, which could be reversed by intrapleu-
ral IL-2 therapy.
T cell exhaustion leads to the dysfunction of CD81 T
cells in tumour progression. Exhausted T cells with high
PD-1 expression are defective in producing cytokines
including IFN-g, tumour necrosis factor (TNF)-a and IL-2
and proliferate poorly [8]. In this study, we found that the
percentages of CD81 T cells expressing GzmB and IFN-g
were reduced, and the proliferation declined in the MPE
compared with that in the PB of LC patients. Our results
were in accord with the literature, which reported that PD-
1 expression on tumour-infiltrating CD81 T cells surface
was higher than that in blood, and that the production of
IL-2, IFN-g and proliferation declined significantly [6].
These results suggest that T cells in MPE are functionally
exhausted, as in tumour tissues.
The down-regulation of PD-1 expression in CD81 T
cells and the restoration of biological functions of IL-2
have been proved in the LCMV chronic viral infection
mouse model [34]. As we observed T cell exhaustion in
MPE, we hypothesized that IL-2 treatment may be an effec-
tive way to alleviate MPE by reverse MPE T cell exhaustion
[25,36]. Indeed, we found that IL-2 therapy reduced PD-1
expression, reversed exhaustion, increased the production
of GzmB, IFN-g and regained the immune function of
CD81 T cells in the MPE of LC patients. These results sug-
gest that reverse T cell exhaustion, including anti-PD-1 and
IL-2 treatment, can be effective ways to manage MPE in LC
patients [24,37].
Accumulating evidence has indicated that down-
regulation of CEA is associated with a good prognosis in
cancer patients after anti-tumour therapy [38,39]. In this
study, we found the CEA levels were reduced after IL-2
therapy in MPE, implying that the malignancy of MPE was
attenuated after IL-2 therapy.
The side effects of IL-2 treatment are correlated highly
with dosage. A low dose of IL-2 can cause vomiting, emesis
and fever ( 388C) for several hours. In contrast, high dose
of IL-2 treatment often lead to more severe side effects, such
as fever, chills, sickness, emesis, fatigue, rash, hypotension,
arrhythmia, myocardial ischaemia and abnormal hepatic and
renal function. Fortunately, these adverse effects could disap-
pear after IL-2 withdrawal [40,41]. In our study, we observed
that some patients had fever, vomiting, emesis and fatigue
after IL-2 treatment which recovered within several hours;
no serious side effects were observed.
In summary, our study demonstrates for the first time
that MPE T cells are phenotypically exhausted, which can
be reversed by IL-2 treatment. IL-2 treatment also reduced
CEA in the MPE. These findings suggest that targeting
mechanisms controlling T cell exhaustion (including PD-
1) would be an effective treatment strategy for controlling
MPE of LC patients.
Fig. 6. IL-2 treatment reduces CEA in the MPE
of LC. (a) CEA concentration in the MPE of LC,
t-test. (b) The percentage reduction of PD-1 and
CEA after IL-2 treatment in the MPE of LC,
t-test. **P< 001; post-treatment versus
pretreatment.
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